What Reinsurance CEOs Must Decide on Mortality Assumptions

The Decision Reinsurance CEOs Cannot Delegate After a Structural Shock

Setting a mortality improvement assumption sounds like actuarial plumbing, the kind of decision that belongs entirely to the technical team and never reaches the executive floor. That assumption stops being plumbing the moment a structural shock puts it in question.

At that point it becomes a genuine strategic decision, because it directly sets the risk appetite, pricing stance, and capital allocation of every life and health reinsurance treaty written until the next review. A CEO who treats this purely as an actuarial update is quietly delegating one of the most consequential calls in the business to a process that, by its own admission, often lags real-world change by years.

Why Is This a CEO-Level Decision, Not Just an Actuarial One?

It is a CEO-level decision because the assumption directly sets pricing competitiveness, risk appetite, and capital allocation for years of future business, choices that sit above any single function.

The actuarial team can measure the deviation and model its implications, but deciding how aggressively to act on an unproven post-shock trend is a strategic call. So is deciding how much margin to hold as a buffer, and how to balance competitive pricing against prudence.

It affects the whole organization's risk posture, not a single line item. It also has direct implications for how the business is positioned relative to competitors who are making the same call with potentially different risk tolerances.

What Is the Core Tradeoff a CEO Faces After a Structural Shock?

The core tradeoff is between moving too fast on unproven post-shock data and overcorrecting, versus waiting too long and writing years of business on a stale assumption.

Every structural shock creates genuine uncertainty about how long its effects will last and how much of the deviation is temporary noise versus a permanent shift. Move too aggressively on early data and the business risks repricing away profitable volume based on a trend that partially reverts.

Wait too long for certainty and the business keeps writing treaties on an assumption that, as the industry's own research has acknowledged, may already be measurably wrong. This is not a problem that resolves itself with more patience.

The Society of Actuaries Research Institute's own RPEC update noted there was "not yet sufficient post-pandemic data upon which to develop an updated MP scale" years after the pandemic's peak, meaning waiting for full certainty could mean waiting indefinitely.

Should a CEO Wait for an Official Updated Scale Before Acting?

Not entirely, since official industry scales can lag actual portfolio experience by a considerable margin, so most executives act on internal monitoring well before an official scale updates.

Waiting for a formal, industry-wide scale revision means accepting whatever lag exists between real experience and the point at which enough data accumulates to satisfy a research body's publication standard. That lag can run years, as documented in the risk-diagnosis discussion in mortality improvement assumptions after structural shocks.

The more common executive approach is to combine internal actual-to-expected monitoring with whatever external guidance exists, treating the official scale as one input rather than the trigger for action.

How Should the CUO Be Involved in This Decision?

The CUO should own the technical assumption review and translate the findings into a concrete recommended pricing and reserving action for the CEO and board to evaluate.

This division of labor keeps the decision grounded in real data while still putting the strategic call where it belongs. The CUO's job is to quantify the deviation, model a range of scenarios for how much of it is temporary versus structural, and present a clear recommendation with its tradeoffs spelled out.

The CEO's job is to weigh that recommendation against the broader competitive and capital picture and make the call. Tools purpose-built for this kind of continuous assumption tracking, such as a Mortality Improvement Trend AI Agent, give the CUO's team the ongoing visibility needed to bring the CEO a well-supported recommendation on a predictable cadence rather than an ad hoc alarm.

How Does This Decision Affect Competitive Positioning, Not Just Internal Risk?

The CEO's call on mortality improvement assumptions directly shapes how competitively the reinsurer can price relative to peers making a different call with the same uncertain data.

Two reinsurers looking at the same post-shock evidence can reasonably reach different conclusions about how much of the deviation is temporary, and that divergence shows up immediately in the market as different pricing. A CEO who moves early and gets the call right wins profitable volume that a more cautious competitor prices away.

A CEO who moves early and gets the call wrong books losses a more disciplined competitor avoided. This is precisely why the decision cannot be treated as a purely defensive, risk-management exercise, it is also a competitive strategy decision with direct market-share consequences either way it resolves.

What Should a CEO Expect From the CUO's Recommendation Before Approving It?

A CEO should expect a recommendation that names the specific data behind it, quantifies a range of outcomes rather than a single point estimate, and states clearly what would change the recommendation.

A recommendation that simply says "we should raise pricing by X" is harder to evaluate and defend than one that says "actual-to-expected mortality has run Y% above assumption for Z consecutive periods across these specific cohorts, here is the range of pricing actions depending on how much of that deviation proves temporary, and here is what additional data would move us from the low end of that range to the high end." The second version gives the CEO something to actually interrogate and defend later, whether to the board, to a rating agency, or to a cedant pushing back on a rate increase.

This standard also protects the CUO. A recommendation built this way survives scrutiny even if it later turns out to be wrong, because the reasoning and evidence trail are documented, which matters enormously when a board or auditor asks, months or years later, why a particular pricing call was made at the time it was made.

What Organizational Capability Does Making This Decision Well Actually Require?

Making this decision well repeatedly requires a standing link between the actuarial function and the executive table, not just individual competence within either group.

Some reinsurers have highly capable actuarial teams and highly capable executives who nonetheless make this decision poorly, because the two groups do not have an established, low-friction channel for moving a data-driven finding into an executive decision quickly. The gap usually is not talent, it is process: no pre-agreed format for escalation, no standing calendar time reserved for exactly this kind of decision, and no shared vocabulary for describing "how confident are we that this deviation is structural" in a way both the actuarial team and the CEO interpret the same way.

Building this organizational capability before a structural shock occurs, not during one, is what separates reinsurers who respond to a shock in weeks from ones who take a year or more to reach a decision, since the second group is not just analyzing new data, it is also building the escalation process itself under time pressure, at exactly the moment that pressure is least helpful.

What Should Trigger a Review Outside the Normal Annual Cycle?

A sustained, multi-period, direction-consistent gap between actual and expected mortality across cohorts should trigger an emergency review regardless of the calendar.

Waiting for the scheduled annual assumption review to catch a structural shift means potentially writing a full year of additional business on a known-wrong assumption. The trigger for an out-of-cycle review should be data-driven, not calendar-driven.

Once actual-to-expected ratios show a consistent pattern across enough periods and enough cohorts to rule out noise, that is the signal to bring the decision to the executive table immediately rather than waiting for the next scheduled checkpoint.

The organizations that handle structural mortality shocks best are not the ones with the most sophisticated actuarial models. They are the ones where the CEO and CUO have already agreed, in advance, on what evidence will trigger a decision and who owns each part of that decision.

That way, when the data does show a persistent deviation, the response is a matter of executing an existing framework rather than debating one from scratch under pressure.

Sources

• Society of Actuaries Research Institute: RPEC 2025 Mortality Improvement Update
• Munich Re: Group Life mortality trends, a post-pandemic perspective